Latest News

• share
• favorite_border

Researchers at the Icahn School of Medicine at Mount Sinai and others have identified a neurodevelopmental disorder, caused by mutations in a single gene, that affects tens of thousands of people worldwide. The work, published in the May 31 online issue of Nature Medicine [DOI: 10.1038/s41591-024-03085-5], was done in collaboration with colleagues at the University of Bristol, UK; KU Leuven, Belgium; and the NIHR BioResource, currently based at the University of Cambridge, UK. The findings will improve clinical diagnostic services for patients with neurodevelopmental disorders.

• share
• favorite_border

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

• share
• favorite_border

Working under the umbrella of the PsychENCODE Consortium, the mental health research project established in 2015 by the National Institutes of Health, a team of Mount Sinai scientists has uncovered important new insights into the molecular biology of neuropsychiatric disease through two new studies published in a special issue of Science on Friday, May 24.

• share
• favorite_border

President of Mount Sinai Fuster Heart Hospital given top honor for his contributions to combating cardiovascular disease worldwide

• share
• favorite_border

The Louis Armstrong Center for Music and Medicine at Mount Sinai is celebrating its 30th anniversary.

• share
• favorite_border

Researchers at the Icahn School of Medicine at Mount Sinai have designed a regenerative medicine therapy to speed up diabetic wound repair. Using tiny fat particles loaded with genetic instructions to calm down inflammation, the treatment was shown to target problem-causing cells and reduce swelling and harmful molecules in mouse models of damaged skin. Details on their findings were published in the May 20 online issue of the Proceedings of the National Academy of Sciences (PNAS).

• share
• favorite_border

Center hosts inaugural conference joined by leaders from across public and private sectors

• share
• favorite_border

Top honor recognizes her commitment to justice, equity, diversity, and inclusion through scholarship, mentorship, and leadership

• share
• favorite_border

Researchers at the Icahn School of Medicine at Mount Sinai have made a significant discovery, identifying genetic connections between inflammatory bowel disease (IBD) and Parkinson’s disease (PD). Published in Genome Medicine on May 13, their study highlights the potential for joint therapeutic strategies to target these two challenging disorders.

• share
• favorite_border

Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients with neuropsychiatric disorders such as depression and anxiety.

• share
• favorite_border

• share
• favorite_border

Miriam Merad, MD, PhD, a world-renowned immunologist, has been appointed Dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai. The appointment reaffirms Icahn Mount Sinai’s commitment to pioneering medical progress and catalyzing the rapid advancement of research innovation. Dr. Merad, the Mount Sinai Professor in Cancer Immunology, will also continue to serve as the founding Chair of the Department of Immunology and Immunotherapy, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute, and Director of the Human Immune Monitoring Center. As Dean, Dr. Merad aims to elevate early clinical trials at Icahn Mount Sinai, streamline the clinical trial process, cultivate a culture of mechanistic clinical trials throughout the campus, and forge stronger partnerships with the pharmaceutical and biotech sectors.